EBITDA increased by 26 per cent to Rs 325 Cr
Alembic Pharmaceuticals reported its consolidated financial results for the second quarter and half year ended September 30, 2025.
Financial highlights for Q2FY26
· Revenue from operations increased by 16 per cent to Rs1,910 Cr.
· EBITDA increased by 26 per cent to Rs 325 Cr
· EBITDA Margin at 17 per cent of revenue
· Reported Profit After Tax at Rs185 Cr up by 20 per cent.
Shaunak Amin, MD, Alembic Pharmaceuticals, said, “Our Q2 performance reflects continued momentum in our core businesses and the disciplined execution. We have strengthened our presence across key markets while maintaining a sharp focus on profitability and operational excellence, delivering an overall growth of 16 per cent and pre-R&D EBITDA margin of 26 per cent. Our R&D investment, at around 10 per cent of revenue, reflects our commitment to building a strong pipeline for future growth. We continue to focus on complex and high-value areas such as injectables, peptides, oral solids, and drug discovery. During the quarter, we completed the acquisition of Utility Therapeutics that provides a segway in to branded drugs in the US.”
Operational Highlights India Branded Business
· India Branded Business delivered a 5 per cent YoY growth, reaching Rs 639 Cr in revenue for the quarter.
· Gynaecology, ophthalmology and animal healthcare segments have demonstrated accelerating performance.
· Cough and Cold segments grew in line with market performance, with robust operational execution.
· Successfully introduced two new products during the quarter.
International Business
· US Generics grew by 21 per cent to Rs. 566 Cr. for the quarter.
· Three launches in the US market during the quarter.
· Ex-US International Generics grew by 31 per cent to Rs 392 Cr. for the quarter.
· Six ANDA approvals received during the quarter, 226 Cumulative ANDA approvals.
API Business
· API business grew by 15 per cent to Rs 261 Cr for the quarter.
